摘要
目的探讨替勃龙与戊酸雌二醇/黄体酮连续联合治疗绝经后女性围绝经期综合征的临床效果。方法选取2018年3月至2021年3月于镇江市妇幼保健院就诊的停经1年以上,Kupperman评分≥16分的绝经后女性围绝经期综合征患者106例为研究对象,按随机数字表法分为替勃龙治疗组(A组,53例)与戊酸雌二醇/黄体酮连续联合治疗组(B组53例)。分别于治疗前后测定患者血清黄体生成素(LH)、促卵泡激素(FSH)及雌二醇(E_(2))水平,运用Kupperman评分量表进行症状评估,并记录不良反应情况。结果治疗后两组FSH、LH水平较治疗前下降,E_(2)水平较治疗前升高,差异有统计学意义(P<0.05),但组间FSH、LH及E_(2)水平比较差异无统计学意义(P>0.05)。治疗后,两组Kupperman评分各症状评分较治疗前有所下降,且B组潮热出汗、失眠及心悸症状评分明显低于A组,而A组疲乏、性生活症状评分明显低于B组,差异有统计学意义(P<0.05)。B组药物不良反应发生率16.98%,略高于A组7.55%,但差异无统计学意义(P>0.05)。结论替勃龙与戊酸雌二醇/黄体酮连续联合用于绝经后女性围绝经期综合征治疗对性激素的改善效果相当,且药物不良反应无显著差异,但戊酸雌二醇/黄体酮连续联合对于潮热出汗、心悸、失眠症状改善效果更好,而替勃龙对于改善疲乏症状及提升性欲方面效果更佳,临床实践应结合患者症状,选择合适的治疗方案。
Objective To explore the clinical effect of tibolone and continuous combination of progynova/progesterone in the treatment of postmenopausal women with perimenopausal syndrome. Methods From March 2018 to March 2021, 106postmenopausal women with perimenopausal syndrome who visited Zhenjiang Maternal and Child Health Care Hospital for more than 1 year of menopause and Kupperman score ≥16 were selected as the observation objects. They were divided into Tibolone treatment group(group A, 53 cases) and progynova/progesterone continuous combination treatment group(group B, 53 cases)according to random number table. The levels of serum luteinizing hormone(LH), follicle-stimulating hormone(FSH) and estradiol(E_(2)) were measured before treatment and after treatment, Kupperman scale was used to assess symptom;adverse reactions were recorded. Results After treatment,the levels of FSH and LH in the two groups were decreased compared with those before treatment, and the level of E_(2) was increased compared with that before treatment,and the difference was statistically significant(P<0.05);there was no significant difference in FSH, LH and E_(2) levels between the two groups(P>0.05). After treatment,the Kupperman symptom scores in the two groups were decreased compared with those before treatment, and the symptom scores of hot flashes, sweating, insomnia and palpitations in group B were significantly lower than those in group A, with significant differences(P<0.05), while the symptom scores of fatigue and decreased libido in group A were significantly lower than those in group B, with significant differences(P<0.05). The incidence of adverse drug reactions in group B was 16.98%, slightly higher than 7.55% in group A, but the difference was not statistically significant(P<0.05). Conclusion Tibolone and continuous combination of progynova/progesterone in the treatment of perimenopausal syndrome in postmenopausal women has the same improvement effect on sex hormones, and there is no significant difference in the adverse drug r
作者
徐静
周小培
XU Jing;ZHOU Xiao-Pei(Department of Women's Health,Zhenjiang Maternal and Child Health Hospital,Zhenjiang 212001,China)
出处
《中国药物经济学》
2023年第3期74-77,共4页
China Journal of Pharmaceutical Economics
